Therapeutic and Prophylactic Effects of  on Dextran Sulfate Sodium-induced Colitis

Woo-Hyeon Jeon; Seok-Jae Ko; Bongha Ryu; Jae-Woo Park; Jeon, Woo-Hyeon; Ko, Seok-Jae; Ryu, Bongha; Park, Jae-Woo

doi:10.13048/jkm.16031

JKM > Volume 37(3); 2016 > Article

Jeon, Ko, Ryu, and Park: Therapeutic and Prophylactic Effects of Zostera Marina on Dextran Sulfate Sodium-induced Colitis

Original Article

The Journal of Korean Medicine 2016; 37(3): 13-26.

Published online: September 30, 2016

DOI: https://doi.org/10.13048/jkm.16031

Therapeutic and Prophylactic Effects of Zostera Marina on Dextran Sulfate Sodium-induced Colitis

Woo-Hyeon Jeon¹, Seok-Jae Ko², Bongha Ryu¹^{, 2}, Jae-Woo Park¹^{, 2}

¹Department of Clinical Korean Medicine, Graduate School, Kyung Hee University

²Department of Gastroenterology, College of Korean Medicine, Kyung Hee University

Correspondence to: 박재우 (Jae-Woo Park), 서울시 동대문구 경희대로 26 경희대학교 한의과대학 비계내과학교실, Tel: +82-2-440-6219, Fax: +82-2-440-7143, E-mail: pjw2907@khu.ac.kr

Received July 15, 2016 Revised September 06, 2016 Accepted September 06, 2016

Abstract

Objectives

Inflammatory bowel disease (IBD) is chronic inflammatory disorders of the intestines. Due to limitation of conventional treatment including steroids, herbal medicines have emerged as possible therapeutic options for IBD. The purpose of the current study was to investigate the therapeutic and prophylactic effects and mechanisms of Zostera Marina water extract (ZME) on DSS-induced colitis.

Methods

Colitis was induced by DSS in Balb/c mice. In pre-treatment setting, ZME was administered 7 days before DSS treatment and in co-treatment setting, ZME was simultaneously administrated with DSS treatment. In both settings, ZME 100, 300 and 1000 mg/kg were orally administered twice a day, respectively. Mice weight and clinical findings were measured daily. Colon length, macroscopic findings and histological damages of colon mucosa were assessed at the end of experiments. The levels of cytokines including TNF-α, IFN-γ, IL-1β, IL-6, IL-10 and IL-17 were measured by Biometric Multiplex Cytokine Profiling method.

Results

In a dose dependent manner, ZME significantly inhibited the colon shortening, and improved macroscopic score and histological score. However, there were insignificant changes on inhibition of weight loss and improvement of clinical score. There were no significant differences of effects between co-treatment and pre-treatment settings. ZME 300 and 1000 mg/kg groups significantly inhibited IFN-γ. Only ZME 1000 mg/kg group significantly inhibited TNF-α, IL-1β and IL-6.

Conclusions

The current results show the possibility of therapeutic use and its prophylactic application of ZME on inflammatory bowel diseases. Future studies for targeted mechanisms of ZME are needed.

Keywords: Zostera Marina, Inflammatory bowel disease, Dextran sulfate sodium, Colitis, Cytokine

Notes

본 논문은 2013년도 경희대학교 대학원 박사학위논문임.

Fig. 1

The Prophylactic Effects of ZME on DSS-induced Colitis

(a) Body weight, (b) Colon length, (c) Clinical score, (d) Colon edema score and (e) Histological findings and scores (A, normal; B, control; C, positive control [Sulfasalazine 30 mg/kg]; D, E and F are ZME-treated groups. The whole colon tissue was stained by H&E. Center was distal part and boundary was proximal part of colon [×100]).

Data are expressed as mean ± S.E.M (n=8). Nor: normal group, Con: control group, P.C: positive control group (Sulfasalazine 30 mg/kg), ZME: Zostera Marina water Extract

***p<0.001, **p<0.01, *p<0.05 vs. control group by one-way ANOVA with Dunnett’s posthoc test.

Fig. 2

The Therapeutic Effects of ZME on DSS-induced Colitis

Data are expressed as mean ± S.E.M (n=8). Nor: normal group, Con: control group, P.C: positive control group (Sulfasalazine 30 mg/kg), ZME: Zostera Marina water Extract

***p<0.001, **p<0.01, *p<0.05 vs. control group by one-way ANOVA with Dunnett’s posthoc test.

Fig. 3

Cytokine Levels of Colon Mucosa

(a) IFN-γ, (b) TNF-α, (c) IL-1β, (d) IL-6, (e) IL-10 and (f) IL-17

Nor: normal group, Con: control group, ZME: Zostera Marina water Extract.

***p<0.001, **p<0.01, *p<0.05 vs. control group by one-way ANOVA with Dunnett’s posthoc test.

Table 1

Clinical score

Score	Spontaneous behavior and posture	Coat and piloerection	Cleaning of perianal region
0	Moving[−] with hunching	Yellowish[light brown] and piloerection[+++]	Herniation with blood[+++]
1	Moving[±] with hunching	Dirty and yellowish[+++] and piloerection[++]	With stool[+++] and blood[+] trace
2	Moving[+] with hunching	Yellowish[++] with piloerection[+]	With stool[++] and blood[+] trace
3	Moving[++] without hunching	Clean and yellowish[+] without piloerection	With stool[+] trace
4	Moving[+++] without hunching	Normal state	Normal state

Table 2

Macroscopic score

Score	Macroscopic score
Score	Thickness of colon edema	Overall health state
0	+++, >0.35 mm	Fecal bleeding[+++] with tar stool[++]
1	++, 0.3–0.35 mm	Fecal bleeding[++] with tar stool[+]
2	+, 0.25–0.3 mm	Fecal bleeding[+] with pasty and semiformed stool
3	±, 0.2–0.25 mm	No bleeding with semiformed stool
4	0.1–0.2 mm	No bleeding with normal stool

참고문헌

1. Yang, SK. Current Status and Clinical Characteristics of Inflammatory Bowel Disease in Korea. Korean J Gastroenterol, (2002). 40, 1-14.

2. Department of Internal Medicine, Medical School, Seoul National University. Guideline of Internal Medicine. 1st ed. Seoul. Korea Medicine Publication;(2002). p. 51-3.

3. Kim JY. Gastrointestinal Disorders. 1st ed. Seoul. Iljogak;(2000). p. 258-76.

4. Park, JW, Bu, Y, Bae, J, Lee, B, Ko, S, & Kim, J, et al. Protective effects of Ulmus macrocarpa on experimental colitis mice models. Orient Pharm Exp Med, (2011). 11, 107-12.

5. Seo, GS, & Choi, SC. Special Review-Ulcerative colitis: Pathophysiology of ulcerative colitis – Relationship with genetics and immunity-. Korean J Med, (2009). 76(7), 643-8.

6. Kim, TH, Kim, BG, Sin, HD, Kim, JW, Kim, CG, & Kim, JS, et al. Alimentary Tract: Tumor Necrosis Factor-a and Interleukin-10 Gen Polymorphisms in Korean Patients with Inflammatory Bowel Disease. Korean J Gastroenterol, (2003). 42, 377-86.

7. Korean Association of Gastroenterology. Inflammatory Bowel Diseases. 1st ed. Seoul. Gunja Publication;(1999). p. 61

8. Siegal, CA. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther, (2011). 33, 23-32.

9. Lee, JY, Kang, HS, Park, BE, Moon, HJ, Sim, SS, & Kim, CJ. Inhibitory effects of Geijigajakyak-Tang on trinitrobenzene sulfonic acid-induced colitis. J Ethnopharmacol, (2009). 126, 244-51.

10. Kim, SY, Ryu, B, & Park, JW. Effects of Samiunkyungtang on inflammation and fecal enzymes in ulcerative colitis animal model. J Korean Med, (2008). 29(3), 56-62.

11. Ryu, B, Ro, W, Park, JW, Bu, Y, Lee, BJ, & Lim, S, et al. Bojanggunbi-tang, a traditional Korean herbal prescription, ameliorates colonic inflammation induced by dextran sulfate sodium and 2,4,6-trinitrobenzene sulfonic acid in mice. J Ethnopharmacol, (2011). 135(2), 582-5.

12. Song, YG, Ryu, B, & Yoon, SW. The Effects of Soyumjungjang-tang on DSS-Induced Ulcerative Colitis in Mouse. Korean J Orient Int Med, (2008). 29(2), 385-400.

13. Hong, SS, Ryu, B, Yoon, SW, & Kim, JS. The effect of Sagunja-tang on TNBS-induced Inflammatory Bowel Disease in Mouse. Korean J Orient Int Med, (2010). 31(4), 731-51.

14. Lee, SW, Ryu, B, & Park, JW. Effects of Sagassum pallidum on 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis in Mice. Korean J Orient Int Med, (2010). 31(2), 224-41.

15. Chung, HL, Yue, GGL, To, KF, Su, YL, Huang, Y, & Ko, WH. Effect of Scutellariae Radix extract on experimental dextran-sulfate sodium-induced colitis in rats. World J Gastroenterol, (2007). 13(42), 5605-11.

16. Choi, HG, Lee, JH, Park, HH, & Sayeghet, FAQ. Antioxidant and Antimicrobial Activity of Zostera marina L. Extract. Algae, (2009). 24(3), 179-84.

17. Harrison, PG. Control of microbial growth and of amphipod grazing by water-soluble compounds from leaves of Zostera marina. Mar Biol, (1982). 67, 225-30.

18. Harrison, PG, & Chan, AT. Inhibition of the growth of micro-algae and bacteria by extracts of eelgrass(Zostera marina) leaves. Mar Biol, (1980). 61, 21-6.

19. Khasina, EI, Kolenchenko, EA, Sgrebneva, MN, Kovalev, VV, & Khotimchenko, YS. Antioxidant activities of a low etherfied pectin from the seagrass Zostera marina. Russian J Mar Biol, (2003). 29, 259-61.

20. Kolenchenko, EA, Sonia, LN, & Khotimchenko, YS. Comparative in vitro assessment of antioxidant activities of a low etherfied pectin from the eelgrass Zostera marina. and antioxidantive medicines. Russian J Mar Biol, (2005). 31, 331-4.

21. Khasina, EI, Tiupeleev, PA, & Sgrebneva, MN. Gastroprotective effect of zosterin, a pectin from seagrass Zostera Marina L. Orient Pharm Exp Med, (2004). 4(4), 253-60.

22. Lee, IA, Bae, EA, Hyun, YJ, & Kim, DH. Dextran sulfate sodium and 2,4,6-trinitrobenzene sulfonic acid induce lipid peroxidation by the proliferation of intestinal gram-negative bacteria in mice. J Inflamm (Lond), (2010). 7, 7.

23. Kitajima, S, Takoma, S, & Morimoto, M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Animal, (2000). 49, 9-15.

24. Song, MY, Park, SY, Kim, JH, Ahn, SH, Kim, KS, & Sohn, IC. Effects of Moxi-tar Herbal Acupuncture of LI11 on inflammatory bowel disease induced by TNBS in mice. Korean J Acupunct, (2008). 25(3), 147-66.

25. Baek, DB, Kwon, OS, Choi, WJ, Kim, JH, Jeon, HY, & Kim, KS, et al. Moxi-tar Herbal Acupuncture of BL25 Acupoint Ameliorates TNBS-Induced Colitis in Mice. Korean J Acupunct, (2007). 24(3), 149-64.

26. Kim, YT, Ahn, SH, Kim, JH, & Sohn, IC. Effects of Moxi-tar Herbal Acupuncture at Cheonchu (ST25) on Crohn’s Disease Induced by TNBS in Mices. Korean J Acupunct, (2008). 25(2), 159-77.

27. Kim, SH, Kim, HJ, Kim, JE, Lee, SH, Hong, SH, & Kim, WI. Clinical Case of Symptoms Remaining after Western Medical Therapy in Ulcerative Colitis, with Herbal Medicine Dansamboheol-tang gagam, Acupuncture, and Moxibustion Treatment. Korean J Orient Int Med, (2007). 28(4), 911-8.

28. Hwang, JW, Choi, HJ, Baik, YS, Jeong, SH, Shin, GC, & Lee, WC. A Case of Pyungwijiyutang-gamibang Diagnosed as Constipation due to Stagnation of Eum with Ulcerative Colitis. Korean J Oriental Int Med, (2007). 28(4), 972-7.

29. Kim CM, Shin MK, Ahn DG, Lee KS. The Great Dictionary of Chinese Herbs (Korean version). 1st ed. Seoul. Jungdam Publication;(1998). p. 6036-7.

30. Kirsner, JB. Experimental colitis with particular reference to hypersensitivity reactions in the colon. Gastroenterology, (1961). 40, 317-22.

31. Okasu, I, Hatakeyama, S, Yamada, M, Ohkusa, T, Inagaki, Y, & Nakaya, R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, (1990). 98, 694-702.

32. MacPherson, BR, & Pfeiffer, CJ. Experimental production of diffuse colitis in rat. Digestion, (1978). 17, 135-50.

33. Morris, GP, Beck, PL, Herridge, MS, Depew, WT, Szewczuk, MR, & Wallace, JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, (1989). 96, 795-803.

34. Strober, W, Fuss, IJ, & Blumberg, RS. The immunology of mucosal models of inflammation. Annu Rev Immunol, (2002). 20, 495-549.

35. Egger, B, Bajaj-Elliott, M, MacDonald, TT, Inglin, R, Eysselein, VE, & Buchler, MW. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion, (2000). 62, 240-8.

36. Ohkusa, T. Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and change in intestinal microflora. Jpn J Gastroenterol, (1985). 82, 1327-36.

37. Kitajima, S, Takoma, S, & Morimoto, M. Chages in colonic mucosal permeability mouse colitis induced with dextran sulfate sodium. Exp Animal, (1999). 48, 137-43.

38. Kim, SJ, Choi, DH, & Chung, YT. Gliotoxin protects against TNBS-induced colitis. via down-regulation of NF-kB activation. Kor J Anat, (2004). 37(3), 309-15.

39. Johswich, K, Martin, M, Bleich, A, Kracht, M, Dittrich-Breiholz, O, & Gessner, JE, et al. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis, (2009). 15, 1812-23.

40. Ko E, Kim JG, Kim JR, Kim HJ, Hong SJ, Park JS, et al. Pathophysiology. 1st ed. Seoul. Korea Medicine Publication;(2006). p. 42-3.

41. O’Shea, JJ, & Murray, PJ. Cytokine signaling modules in inflammatory responses. Immunity, (2008). 28, 477-87.

42. Pizarro, TT, & Cominelli, F. Cytokine therapy for Crohn’s disease: advances in translational research. Annu Rev Med, (2007). 58, 433-44.

43. Dionne, S, Hiscott, J, D’Agata, I, Duhaime, A, & Seidman, EG. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci, (1997). 42, 1557-66.

44. Targan, SR, Hanauer, SB, Van Deventer, SJ, Mayer, L, Present, DH, & Braakman, T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med, (1997). 337, 1029-35.

45. Kwon HH, Kim EJ, Kim IT, Park KH, Yang MG, Eum YB, et al. Clinical Immunology. 1st ed. Seoul. Korean Medicine Publication;(2010). p. 158-70.

46. Barnes, PJ, & Karin, M. Nuclear factor-KB-a pivotal transcription factor in chronic inflammatory disease. N Engl J Med, (1997). 336, 1066-71.

47. Fedorak, RN, Gangl, A, Elson, CO, Rutgeerts, P, Schreiber, S, & Wild, G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. Gastroenterology, (2000). 119, 1473-82.

48. Schreiber, S, Fedorak, RN, Nielsen, OH, Wild, G, Williams, CN, & Nikolaus, S, et al. Safety and efficacy of recombinant human interleukin-10 in chronic active Crohn’s disease. Gastroenterology, (2000). 119, 1461-72.

49. Fujino, S, Andoh, A, Bamba, S, Ogawa, A, Hata, K, & Araki, Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut, (2003). 52, 65-70.